Highest-materiality recent filing
Xenetic-Santersus share exchange values combined company at $141M; XBIO holders ~15%
Deal values Xenetic at ~$21M (15% pro forma) and Santersus at ~$120M (85%); 2,546,699 XBIO shares outstanding.
Xenetic to acquire Santersus in all-stock deal; combined company to trade as SNTS
Share exchange: Xenetic acquires all Santersus shares; Santersus holders to own ~85% of combined company.
Xenetic Biosciences adjourns 2025 Annual Meeting again; no quorum achieved
Annual Meeting adjourned from Dec 11, 2025 to Jan 8, 2026 to seek quorum; reconvened but still lacked quorum.
Xenetic Biosciences Q3 net loss ~$0.5M, revenue up 67% to $1.0M; cash extended by $3.9M offering
Net loss of approximately $0.5M for Q3 2025; revenue rose 67% YoY to $1.0M on higher Takeda royalty payments.
Xenetic extends Scripps collaboration with $400k funding for DNase platform
Extended Research Funding & Option Agreement with Scripps Research by 12 months; total funding up to ~$400,000.
James Parslow appointed Interim CEO effective May 16, 2024; base salary increased to $400,000.
Xenetic Biosciences CEO Eisenberg and CSO Lockshin depart; CFO Parslow named interim CEO
Jeffrey F. Eisenberg stepped down as CEO and resigned as director effective May 16, 2024.
Xenetic Biosciences reports FY2023 net loss of $4.1M; cash at $9.0M
Net loss of $4.1M for year ended Dec 31, 2023; R&D expenses down 26.7% to $3.5M.
Xenetic Biosciences reports Q3 net loss of $1.1M; R&D spend up 156% on DNase platform
Net loss of $1.1M for Q3 2023; cash at $9.8M.
Xenetic Biosciences announces 1-for-10 reverse stock split effective May 15, 2023
Reverse split reduces outstanding shares from 15,166,596 to ~1,516,660; authorized shares from 100M to 10M.
Xenetic Biosciences FY 2022 net loss $6.6M; cash $13.1M; DNase platform advances toward Phase 1
Net loss for FY 2022 was approximately $6.6 million; R&D expenses rose 50.8% to $4.8M.
Xenetic Biosciences receives Nasdaq extension to May 29, 2023 to regain $1 bid price compliance
Nasdaq granted an additional 180 calendar days, until May 29, 2023, to meet the $1.00 minimum bid price requirement.
Xenetic Biosciences reports Q2 net loss of $2.7M; advances DNase platform toward Phase 1 study
Net loss of approx $2.7M for Q2 2022; R&D expense rose 296% to $2.1M, including $1.3M IPR&D for DNase license.
Xenetic enters manufacturing agreement with Catalent for DNase clinical supply up to $5M
Estimated project cost up to ~$5M for cGMP manufacturing of Human DNase I over ~17 months.
Upfront payment: $500K cash + 875,000 common shares (250,000 issued to OPKO per third-party obligation).
Xenetic Biosciences reports Q3 net loss of ~$1.4M; cash $19.7M after $12.5M private placement
Net loss ~$1.4M for Q3 2021; R&D expenses up 36.1% to $0.8M, G&A up 17.5% to $0.9M.
On October 29, 2024, James E. Callaway and Adam Logal, each a member of the board of directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”), informed the Company of their intention to not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders.
On October 29, 2024, James E. Callaway and Adam Logal, each a member of the board of directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”), informed the Company of their intention to not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders.
and Curtis Lockshin, the Company’s former Chief Scientific Officer
the Company entered into a confidential separation agreement and general release with each of and Jeffrey F. Eisenberg, the Company’s former Chief Executive Officer
the Board of Directors of Xenetic Biosciences, Inc. (the “Company”) appointed James F. Parslow, the Company’s Chief Financial Officer, to the position of Interim Chief Executive Officer.
and in connection therewith, Mr. Eisenberg resigned as a director of the Company and all of its subsidiaries, as applicable.
In addition on May 16, 2024, the Company and Dr. Curtis Lockshin mutually agreed that Dr. Lockshin would step down as the Chief Scientific Officer of the Company, effective immediately.
On May 16, 2024, the Company and Jeffrey F. Eisenberg mutually agreed that Mr. Eisenberg would step down as the Chief Executive Officer of the Company, effective immediately
On May 16, 2024, the Board of Directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”) appointed James F. Parslow, the Company’s Chief Financial Officer, to the position of Interim Chief Executive Officer.
On July 15, 2021, Dr. Dmitry Genkin resigned as a member of the Board of Directors of Xenetic Biosciences, Inc.
Max materiality 0.95 · Median 0.50 · Most common event earnings